Jose A. Simon-Antonio

Sevilla, AN 41013, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Bridging preclinical development and clinical manufacturing: a translational GMP-Platform for lentiviral vector production in academic CAR T-Cell therapy.

Bridging preclinical development and clinical manufacturing: a translational GMP-Platform for lentiviral vector production in academic CAR T-Cell therapy.

Journal: Journal of translational medicine

Published: May 06, 2026

Bridging preclinical development and clinical manufacturing: a translational GMP-Platform for lentiviral vector production in academic CAR T-Cell therapy.

Bridging preclinical development and clinical manufacturing: a translational GMP-Platform for lentiviral vector production in academic CAR T-Cell therapy.

Journal: Journal of translational medicine

Published: May 06, 2026

Metabolic and functional analysis including repetitive antigen stimulation provides a more accurate assessment for CAR-T cell product quality and long-term functionality.

Metabolic and functional analysis including repetitive antigen stimulation provides a more accurate assessment for CAR-T cell product quality and long-term functionality.

Journal: Journal of translational medicine

Published: December 01, 2025

Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories.

Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories.

Journal: Leukemia research

Published: September 22, 2025

Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies.

Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies.

Journal: Journal of translational medicine

Published: April 07, 2025

GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation.

GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation.

Journal: Bone marrow transplantation

Published: October 21, 2024

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: August 09, 2024

Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.

Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.

Journal: Bone marrow transplantation

Published: June 16, 2024

Monocytosis as prognostic factor for chronic graft versus host disease.

Monocytosis as prognostic factor for chronic graft versus host disease.

Journal: Bone marrow transplantation

Published: March 11, 2024

Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions.

Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions.

Journal: British journal of cancer

Published: July 04, 2023

Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment.

Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment.

Journal: Transplantation and cellular therapy

Published: November 06, 2021

Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease.

Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease.

Journal: Bone marrow transplantation

Published: March 23, 2021

Showing 1-12 of 27

Last Updated: 09/26/2026